ADENOCARD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADENOCARD (adenosine) is a small-molecule injectable therapeutic approved in 1989. The generic name and mechanism of action are not specified in available data, but it is administered via injection. This product represents an established, long-marketed injectable in the Astellas portfolio.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team will likely shift focus toward lifecycle management, cost optimization, and preparation for generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADENOCARD currently has zero linked job openings, reflecting its mature lifecycle stage. Career opportunities on this product are limited and declining, with focus shifting toward defensive market positioning and cost management rather than growth initiatives.
Brand ManagerProduct Manager
Worked on ADENOCARD at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.